Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Revolution Medicines, Inc.RVMD · Entity 606 | SVP & General Counsel | September 25, 2026 | September 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Revolution Medicines, Inc.
Report date September 25, 2026 · Filed September 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,776 |
Reported balance
After 2026-09-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-25 · Sale · Disposed 765 · Balance 51,776 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. F2: Includes 37,088 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026.
F2: Includes 37,088 restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 25, 2026 Filed Sep 30, 2026 02:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 765 | $207.32 | $158,599.88 |
DisclosureSEC source: 0001969082-26-000011 · ownership.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,776 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. F2 · balance_after: Includes 37,088 restricted stock units. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 22:01 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 3,314 | $199.30 | $660,490.80 |
DisclosureSEC source: 0001969082-26-000009 · ownership.xml · nonDerivative · entry 2 Cislini Jeff · CIK 0001969082 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,541 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F3 · balance_after: Includes 37,088 restricted stock units. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 22:01 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 52 | $195.01 | $10,140.45 |
DisclosureSEC source: 0001969082-26-000009 · ownership.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,855 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F2 · price: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 20:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,600 | $0.00 Strike: $21.61 | $0.00 |
DisclosureSEC source: 0001610717-26-000388 · form4.xml · derivative · entry 10 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 26,600 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. F9 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from September 1, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 20:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 29,680 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0001610717-26-000388 · form4.xml · derivative · entry 9 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,680 shares Expires 2032-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 20:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 3,314 | $212.06 | $702,761.21 |
DisclosureSEC source: 0001610717-26-000388 · form4.xml · nonDerivative · entry 8 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,907 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. F8 · price: This transaction was executed in multiple trades in prices ranging from $211.77 to $212.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 43,514 restricted stock units. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 20:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 4,500 | $211.34 | $951,037.65 |
DisclosureSEC source: 0001610717-26-000388 · form4.xml · nonDerivative · entry 7 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,221 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. F7 · price: This transaction was executed in multiple trades in prices ranging from $210.77 to $211.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 43,514 restricted stock units. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 20:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,540 | $210.26 | $534,072.34 |
DisclosureSEC source: 0001610717-26-000388 · form4.xml · nonDerivative · entry 6 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,721 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. F6 · price: This transaction was executed in multiple trades in prices ranging from $209.77 to $210.72, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 43,514 restricted stock units. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 20:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 25,817 | $209.25 | $5,402,199.50 |
DisclosureSEC source: 0001610717-26-000388 · form4.xml · nonDerivative · entry 5 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,261 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. F5 · price: This transaction was executed in multiple trades in prices ranging from $208.77 to $209.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 43,514 restricted stock units. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 20:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 17,323 | $208.37 | $3,609,572.72 |
DisclosureSEC source: 0001610717-26-000388 · form4.xml · nonDerivative · entry 4 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,078 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. F4 · price: This transaction was executed in multiple trades in prices ranging from $207.765 to $208.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 20:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 3,400 | $207.24 | $704,603.42 |
DisclosureSEC source: 0001610717-26-000388 · form4.xml · nonDerivative · entry 3 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,401 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. F3 · price: This transaction was executed in multiple trades in prices ranging from $206.76 to $207.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 43,514 restricted stock units. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 20:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 26,600 | $21.61 | $574,826.00 |
DisclosureSEC source: 0001610717-26-000388 · form4.xml · nonDerivative · entry 2 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. F2 · balance_after: Includes 43,514 restricted stock units. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 20:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 29,680 | $18.56 | $550,860.80 |
DisclosureSEC source: 0001610717-26-000388 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. F2 · balance_after: Includes 43,514 restricted stock units. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:10 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,157 | $156.12 | $336,748.90 |
DisclosureSEC source: 0001610717-26-000245 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,521 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8251. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes 43,514 RSUs. F4 · balance_after: Includes 160 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026. Read SEC document |
| March 19, 2026 Filed Mar 19, 2026 22:54 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,163 | $97.44 | $113,322.72 |
DisclosureSEC source: 0001610717-26-000127 · form4.xml · nonDerivative · entry 2 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,518 F3 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025. F2 · balance_after: Includes 48,125 RSUs. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 22:54 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,795 | $99.48 | $178,567.32 |
DisclosureSEC source: 0001610717-26-000127 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,681 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 48,125 RSUs. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 02:08 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 32,500 | $0.00 Strike: $102.02 | $0.00 |
DisclosureSEC source: 0001610717-26-000080 · form4.xml · derivative · entry 2 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2036-02-28 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 02:08 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 14,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000080 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,476 F1 · balance_after: Includes 53,269 restricted stock units. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 21:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 908 | $115.60 | $104,964.80 |
DisclosureSEC source: 0001610717-26-000018 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,976 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025. F2 · balance_after: Includes 38,769 restricted stock units. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:17 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,688 | $76.82 | $206,483.83 |
DisclosureSEC source: 0001610717-25-000424 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,884 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 147 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2025. F3 · balance_after: Includes 38,769 restricted stock units. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 21:23 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,388 | $0.00 Strike: $42.45 | $0.00 |
DisclosureSEC source: 0001610717-25-000383 · form4.xml · derivative · entry 3 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,388 shares Expires 2031-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 21:23 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 13,388 | $70.14 | $939,007.54 |
DisclosureSEC source: 0001610717-25-000383 · form4.xml · nonDerivative · entry 2 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,425 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025. F3 · price: This transaction was executed in multiple trades in prices ranging from $70.00 to $70.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 43,910 restricted stock units. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 21:23 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 13,388 | $42.45 | $568,320.60 |
DisclosureSEC source: 0001610717-25-000383 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025. F2 · balance_after: Includes 43,910 restricted stock units. Read SEC document |
| October 17, 2025 Filed Oct 20, 2025 20:19 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $36.57 | $0.00 |
DisclosureSEC source: 0001610717-25-000368 · form4.xml · derivative · entry 3 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025. Read SEC document |
| October 17, 2025 Filed Oct 20, 2025 20:19 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 12,000 | $55.00 | $660,000.00 |
DisclosureSEC source: 0001610717-25-000368 · form4.xml · nonDerivative · entry 2 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,425 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025. F2 · balance_after: Includes 43,910 restricted stock units. Read SEC document |
| October 17, 2025 Filed Oct 20, 2025 20:19 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 12,000 | $36.57 | $438,840.00 |
DisclosureSEC source: 0001610717-25-000368 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025. F2 · balance_after: Includes 43,910 restricted stock units. Read SEC document |
| September 24, 2025 Filed Sep 26, 2025 20:13 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,799 | $44.26 | $79,623.74 |
DisclosureSEC source: 0001610717-25-000353 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,425 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025. F2 · balance_after: Includes 43,910 restricted stock units. Read SEC document |
| September 16, 2025 Filed Sep 18, 2025 20:35 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,869 | $45.82 | $85,646.74 |
DisclosureSEC source: 0001610717-25-000347 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,224 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 43,910 restricted stock units. Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 20:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,912 | $39.61 | $75,735.85 |
DisclosureSEC source: 0001610717-25-000250 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,093 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025. F2 · price: This transaction was executed in multiple trades in prices ranging from $39.26 to $40.05, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 49,054 restricted stock units. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,878 | $39.83 | $74,800.74 |
DisclosureSEC source: 0001610717-25-000240 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,005 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $39.5915 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 160 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025. F4 · balance_after: Includes 49,054 RSUs. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 20:55 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,041 | $38.71 | $79,008.13 |
DisclosureSEC source: 0001610717-25-000088 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,723 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 20, 2024. F2 · price: This transaction was executed in multiple trades in prices ranging from $38.49 to $38.91, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 54,195 restricted stock units. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 21:43 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,458 | $39.04 | $56,920.76 |
DisclosureSEC source: 0001610717-25-000081 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,764 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 54,195 RSUs. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 00:03 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 77,000 | $0.00 Strike: $40.74 | $0.00 |
DisclosureSEC source: 0001610717-25-000056 · form4.xml · derivative · entry 2 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2035-02-28 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 00:03 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000056 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,222 F1 · balance_after: Includes 58,204 restricted stock units. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 22:30 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,406 | $40.50 | $97,443.00 |
DisclosureSEC source: 0001610717-25-000012 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,222 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 20, 2024. F2 · balance_after: Includes 36,204 restricted stock units. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:07 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,599 | $45.40 | $72,600.68 |
DisclosureSEC source: 0001610717-24-000544 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,628 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 147 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2024. F3 · balance_after: Includes 36,204 RSUs. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,554 | $55.13 | $140,811.47 |
DisclosureSEC source: 0001610717-24-000525 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,080 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 20, 2024. F2 · price: This transaction was executed in multiple trades in prices ranging from $54.91 to $55.51, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 40,209 restricted stock units. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:20 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $36.57 | $0.00 |
DisclosureSEC source: 0001610717-24-000518 · form4.xml · derivative · entry 3 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 6,000 shares Expires 2030-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 20, 2024. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:20 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 6,000 | $60.00 | $360,000.00 |
DisclosureSEC source: 0001610717-24-000518 · form4.xml · nonDerivative · entry 2 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,634 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 20, 2024. F2 · balance_after: Includes 40,209 restricted stock units. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:20 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 6,000 | $36.57 | $219,420.00 |
DisclosureSEC source: 0001610717-24-000518 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 20, 2024. F2 · balance_after: Includes 40,209 restricted stock units. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 21:29 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $36.57 | $0.00 |
DisclosureSEC source: 0001610717-24-000506 · form4.xml · derivative · entry 3 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 6,000 shares Expires 2030-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 20, 2024. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 21:29 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 6,000 | $50.17 | $301,026.60 |
DisclosureSEC source: 0001610717-24-000506 · form4.xml · nonDerivative · entry 2 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,634 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 20, 2024. F2 · price: This transaction was executed in multiple trades in prices ranging from $50.00 to $50.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 40,209 restricted stock units. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 21:29 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 6,000 | $36.57 | $219,420.00 |
DisclosureSEC source: 0001610717-24-000506 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 20, 2024. F3 · balance_after: Includes 40,209 restricted stock units. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 20:16 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,454 | $44.19 | $64,245.43 |
DisclosureSEC source: 0001610717-24-000485 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,634 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 40,209 restricted stock units. Read SEC document |
| July 09, 2024 Filed Jul 10, 2024 20:36 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,399 | $40.83 | $97,951.17 |
DisclosureSEC source: 0001610717-24-000395 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,088 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 20, 2024. F2 · balance_after: Includes 44,217 restricted stock units. Read SEC document |
| June 26, 2024 Filed Jun 27, 2024 22:48 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,000 | $38.47 | $76,939.60 |
DisclosureSEC source: 0001610717-24-000368 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,487 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 20, 2024. F2 · price: This transaction was executed in multiple trades in prices ranging from $38.11 to $38.80, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 44,217 restricted stock units. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:11 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,757 | $37.39 | $65,689.66 |
DisclosureSEC source: 0001610717-24-000348 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,487 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $37.3845 to $37.3904, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 370 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2024. F4 · balance_after: Includes 44,217 RSUs. Read SEC document |
| May 21, 2024 Filed May 22, 2024 20:11 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 800 | $39.51 | $31,604.88 |
DisclosureSEC source: 0001610717-24-000256 · form4.xml · nonDerivative · entry 2 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,874 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 27, 2023. F4 · price: This transaction was executed in multiple trades in prices ranging from $39.22 to $39.88, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 48,972 restricted stock units. Read SEC document |
| May 21, 2024 Filed May 22, 2024 20:11 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 700 | $38.67 | $27,065.99 |
DisclosureSEC source: 0001610717-24-000256 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,674 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 27, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $38.14 to $39.12, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 48,972 restricted stock units. Read SEC document |
| March 27, 2024 Filed Mar 28, 2024 20:11 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 800 | $31.52 | $25,212.00 |
DisclosureSEC source: 0001610717-24-000189 · form4.xml · nonDerivative · entry 2 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,374 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 27, 2023. F4 · price: This transaction was executed in multiple trades in prices ranging from $31.38 to $31.68, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 48,972 restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.